Raf kinase inhibitor, sorafenib

One notable example of HTS providing a lead structure with a novel chemotype and a novel mechanism of action 

At the time of discovery, the thienylurea lead structure 22 represented a novel structural class for kinase inhibition. Concurrently, similar structures were identified as inhibitors of P38 MAP kinase, an enzyme involved in the regulation of inflammation. Subsequently, it was shown that sorafenib inhibits Raf-1 by binding to an inactive conformation of the enzyme, a mechanism of action that has also been observed for other kinase inhibitors.  

---